drugset

Drugs / NOVA22007

Follow last change May 2022 re-read 3 minutes ago

NOVA22007

also known as Cyclosporine

Developed for: dry eye syndrome
Investigated by: Santen SAS

Trials 1

today NCT00739349 · Ph 2

2009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT00739349	Aug 2008 → Jan 2009	dry eye syndrome	Santen SAS	Completed	No outcome recorded

Press releases naming this drug 3 releases

Date	Issuer	Release
2022-05-02	Santen Gmbh	Santen's Verkazia (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States santen.com ↗
2021-06-24	Santen Gmbh	Santen Receives U.S. FDA Approval for Verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the Treatment of Vernal Keratoconjunctivitis in Children and Adults santen.com ↗
2020-10-26	Santen Gmbh	Santen Announces U.S. FDA Filling Acceptance of New Drug Application(NDA) for Cyclosporine Topical Ophthalmic Emulsion, 0.1% in the Treatment of Severe Vernal Keratoconjunctivitis in Patients Ages 4-18 santen.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	NOVA22007	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00739349 ↗
Known as	Cyclosporine	“NOVA22007 ''Cyclosporine''” NCT00739349 ↗